Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01706913 · ClinicalTrials.gov registry record · NA

Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
246
Enrollment target

NCT01706913: Completed NA study, sponsored by Massachusetts General Hospital.

NCT01706913 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 246 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01706913, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
246 participants
Enrollment target

Study Summary

This is a randomized, controlled study to compare patients evaluated and managed by internal medicine hospitalists alone versus patients who are additionally evaluated by a dermatologist when they are admitted to the hospital, aiming to demonstrate that hospital admissions for cellulitis that involve early dermatology consultation will reduce hospital length of stay, readmission rates, prevalence of pseudocellulitis, cost, and antibiotic usage. The hypothesis of this study is that obtaining inpatient dermatology consultations, within 24 hours of a patient being admitted to the hospital for cellulitis, will reduce the length of stay, readmission rate, cost, and antibiotic usage of the patient"s admission as well as properly evaluate and diagnose patients with pseudocellulitis. The primary objective will be to measure the difference in the length of stay for patients who are randomized to a dermatology consultation within 24 hours of hospital admission (active arm) versus being managed by an internal medicine hospitalist alone, as is the standard of care (control arm). The length of stay for each arm will be assessed once the study has been completed. The secondary endpoint will be to measure readmission rates for cellulitis after patients are discharged from the hospital. An additional endpoint will be to determine if antibiotic usage differs between patients randomized to a dermatology consultation and those not. Exploratory analyses will assess the percentage of patients with a concomitant known predisposing factor for recurrent cellulitis such as lymphedema, leg ulceration, tinea pedis, or onychomycosis, as well as the association of fever \>100.5 F and a history of a prior episode of cellulitis.

Primary Outcome

We will be measuring the difference between antibiotic usage in patients in the control group as compared with the treatment group

Interventions

  • OTHER Dermatology consult

Trial Details

FieldValue
Enrollment Target 246 participants
Start Date 2012-10
Est. Completion 2018-12-31
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT01706913 record still lists

NCT01706913 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 1 intervention - of which Dermatology consult is the first listed.

NCT01706913 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01706913 about?

NCT01706913 is a clinical study titled "Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis". This is a randomized, controlled study to compare patients evaluated and managed by internal medicine hospitalists alone versus patients who are additionally evaluated by a dermatologist when they are admitted to the hospital, aiming to demonstrate that hospital admissions for cellulitis that involv...

What is the current status of trial NCT01706913?

This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2012-10. Estimated completion is 2018-12-31.

What interventions are being tested in trial NCT01706913?

The interventions under investigation include: Dermatology consult (OTHER).

Who is sponsoring clinical trial NCT01706913?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01706913's enrollment target sits among peer trials

246 436th of 2000 higher than 1,565 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04973605 · 246 participants · Phase 1

    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  • NCT06395168 · 246 participants · NA

    Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination

  • NCT07048769 · 246 participants · Phase 4

    Paracervical Block for Pain Reduction in Saline Infusion Sonograms

  • NCT07176650 · 246 participants · Phase 1

    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01706913, the US trial registry maintained by the National Library of Medicine. NCT01706913 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.